Indegene Ltd (INDGN) DCF Value Analysis March 2026

Indegene Ltd (INDGN) — Investment Research Report
EQUITY RESEARCH  |  HEALTHCARE TECHNOLOGY  |  NSE: INDGN  |  BSE: 544172
March 2026  |  For Informational Purposes Only
CMP ₹452 | 52W H ₹633 | 52W L ₹414 | Mkt Cap ₹10,887 Cr | P/E 24.8x | ROCE 24.8% | ROE 20.6%
Investment Research Report · Initiating Coverage

Indegene Limited
Digital Healthcare at an Inflection

A digital-first life sciences technology company with a robust 30% revenue growth trajectory, navigating margin pressures while building a scalable global platform for biopharma commercialisation.
Healthcare Technology
₹10,887 Cr
₹580
+28%
ACCUMULATE
Medium–High
₹3,263 Cr
+18% YoY growth
₹439 Cr
+30% vs FY24
18–20%
Stable EBITDA band
68%
FY20–FY25

Business Overview

Section 01
01

Incorporated in 1998 and listed on the NSE/BSE in May 2024, Indegene Limited is a digital-first, end-to-end healthcare and technology company headquartered in Bengaluru. The company serves biopharmaceutical, emerging biotech, and medical device companies globally, helping them develop, commercialise, and manage products across the entire product lifecycle.

The company’s offering spans four broad solution pillars: Commercial Solutions (medical content, digital marketing, omnichannel engagement for HCPs and patients), Medical, Regulatory & Safety (MRS) (medical writing, pharmacovigilance, regulatory submissions), Data & Analytics, and an increasingly important Technology Platform layer powered by its proprietary BiologX and INDEGENE360 platforms.

Indegene’s addressable universe is the ~$30 billion global life sciences services market. Its key differentiator is the rare combination of deep domain expertise in healthcare with technology scalability — a moat that pure-play IT services or CROs struggle to replicate. Its client roster includes 18 of the top-20 global biopharma companies, providing strong revenue visibility and low client concentration risk at scale.

The company went public at ₹452/share in May 2024 and has been volatile since, impacted by margin headwinds, large PE-backed stake sales, and broader small-cap underperformance. The current price of ~₹452 represents a compelling re-entry near IPO price after the stock peaked at ₹736 in mid-2024.

Historical Financial Performance

Section 02
02
Metric (₹ Cr)FY21FY22FY23FY24FY25TTM
Revenue9661,6652,3062,5902,8393,263
Revenue Growth %50%72%38%12%10%18%
Operating Profit (EBIT)230287396505548603
OPM %24%17%17%20%19%18%
Net Profit149163266337407439
EPS (₹)——11.9915.1416.9518.28
Free Cash Flow172 Cr297 Cr130 Cr508 Cr442 Cr~460 Cr est.

Q3 FY26 Snapshot: Revenue surged 30.8% YoY to ₹942 Cr (a record quarter), driven by large MRS deal ramp-ups and acquisitions of BioPharm Communications and Warn & Co. However, net profit dipped 6.2% YoY to ₹102.9 Cr, reflecting integration costs and higher depreciation from M&A. Adjusted EBITDA grew 15.7% YoY to ₹174.7 Cr at a margin of ~18.5%.

The company remains nearly debt-free (borrowings down from ₹490 Cr in FY24 to ₹102 Cr in FY25), with reserves expanding to ₹2,568 Cr. This gives meaningful balance sheet headroom for further acquisitions or capital returns.

DCF Valuation

Section 03
03

10-Year Free Cash Flow Discounted Model

₹442 Cr
18% (Yr 1–5)
15–17%
12%
5%
₹580/share

Model assumes FCF grows from ₹442 Cr (FY25) to ~₹1,650 Cr by FY35 (Yr 10), anchored by 18% revenue CAGR tapering to 12% in Yr 6–10, with FCF margins steady at 15–17%. Terminal value discounted at 12% WACC with 5% perpetuity growth, then discounted back over 10 years. Shares outstanding: ~24 Cr (FY25). DCF intrinsic value = ₹580/share. Current CMP of ₹452 implies ~22% margin of safety to base case.

Buying Range

Section 04
04
Three-Zone Entry Framework · Based on DCF Intrinsic Value of ₹580
Below ₹430
35%+ margin of safety. Aggressive accumulation recommended. Near 52-week low support.
₹430 – ₹510
Current range. 14–25% margin of safety. Suitable for SIP-based accumulation. CMP ₹452 falls here.
₹510 – ₹580
Approaching fair value. Enter only on dips or corrections. Analyst consensus target ~₹611.

Scenario Analysis

Section 05
05
₹310
−31% from CMP
Revenue CAGR slows to 10%. Margins compress to 14–15% on sustained integration costs. Key client losses, US pharma spending cuts, AI-led content commoditisation. P/E de-rates to 18x.
₹580
+28% from CMP
Revenue CAGR of 18%. EBITDA margins stabilise at 18–20%. Steady M&A integration, 2–3 more bolt-on deals in MRS/digital. EPS grows to ₹25+ by FY27. P/E re-rates to 25x.
₹780
+73% from CMP
Revenue CAGR 25%+, driven by AI-powered products, FDA-adjacent tech wins, major large-deal ramp. Margins expand to 22%. EPS exceeds ₹32 by FY27. P/E re-rates to 28–30x on premium multiple.

Future Growth & Earnings Potential

Section 06
06

Revenue Growth Engine: Indegene reported its first-ever quarter exceeding ₹100M (USD) in revenue in Q1 FY26. Management has guided for sustained 20%+ organic growth, further boosted by acquisitions of BioPharm Communications (Canada) and Warn & Co (Europe), expanding its global MRS footprint. Analysts expect FY26 revenue of ~₹3,500–3,600 Cr (+20.7% YoY per Trendlyne consensus).

AI Integration — the growth wildcard: Indegene is aggressively embedding generative AI into its content, regulatory, and pharmacovigilance workflows. Management highlighted AI-driven productivity gains in the Q3 FY26 earnings call. This could either expand margins by reducing headcount per engagement, or be passed on to clients as pricing competitiveness — both scenarios being long-term positives.

EPS Trajectory: With consensus EPS of ₹21–24 for FY27 and ~30% profit growth CAGR over the last 3 years, EPS growth of 12–15% is the conservative path. At 25x P/E on ₹24 EPS (FY27E), fair value arrives at ₹600. At 28x on the bull case EPS of ₹28, target is ₹784.

Dividend policy: Indegene initiated its maiden dividend of ₹2/share in FY25 (12% payout). This is likely to grow modestly, but given strong reinvestment opportunities through M&A, do not expect high dividend yields in the near term.

Risks & Catalysts

Section 07
07

Catalysts (Bull Triggers)

Large deal wins from top-10 global pharma clients in MRS or AI-powered commercialisation
Successful integration of BioPharm + Warn & Co driving margin recovery in H1 FY27
Launch of proprietary AI SaaS products monetised via subscription, improving revenue quality
PE overhang clears — CA Dawn Investments fully exits, unlocking price discovery
Nifty Midcap 150 re-inclusion or index upgrade catalysing institutional buying

Risks (Bear Triggers)

US pharmaceutical R&D budget cuts amid macro pressures — key demand driver vulnerable
AI commoditises medical content creation, compressing commercial segment pricing power
Integration risk from multiple acquisitions — BioPharm, Warn & Co, plus potential future deals
Continued PE stake sales (promoters hold 0%) keep overhang on the stock for 12–18 months
Currency risk: ~70%+ revenues USD/EUR denominated; INR appreciation headwind

Peer Comparison

Section 08
08
CompanyMkt Cap (Cr)Revenue (Cr)OPM%P/EROE%3Y Rev CAGR
Indegene (INDGN)10,8873,263 (TTM)18%24.8x20.6%19%
Divi’s Laboratories1,23,0008,96928%68x14%6%
Metropolis Healthcare7,2001,32022%38x18%12%
Syngene International14,5003,80024%30x15%14%
IQVIA India (global peer)—~USD 15Bn15%22x—8%

Indegene trades at a 24.8x P/E — a meaningful discount to peers like Syngene (30x) and Metropolis (38x), despite delivering superior revenue CAGR of 19% over 3 years. The valuation discount is partly justified by the lack of a promoter holding and near-term margin compression, but represents an opportunity as those headwinds resolve. On an EV/EBITDA basis, Indegene trades at approximately 18–20x, reasonable for a 20%+ growth business with improving cash conversion.

Investment Verdict

A Digital Healthcare Compounder
Available at IPO Prices

Indegene is a rare combination: a structurally high-growth business (19% 3Y revenue CAGR, 68% 5Y profit CAGR) available at or below its May 2024 IPO price. The stock has been punished by PE overhang, M&A integration uncertainty, and small-cap sentiment — none of which impair the fundamental business thesis. The Q3 FY26 revenue print of ₹942 Cr (+30.8% YoY) confirms the top-line engine is firing. Margin recovery as acquisitions integrate in FY27 is the key re-rating trigger. At CMP of ₹452, with our DCF-derived intrinsic value of ₹580 (base) and analyst consensus of ₹611, we rate the stock ACCUMULATE with a 12–18 month horizon. SIP accumulation in the ₹430–510 zone is recommended.

Our Rating
ACCUMULATE
₹580
₹611
+28%

Disclaimer: This report is prepared for informational and educational purposes only. It does not constitute investment advice, a solicitation, or an offer to buy or sell any securities. The intrinsic value estimates, price targets, and financial projections are based on publicly available data and are subject to significant uncertainty. Past performance is not indicative of future results. Investing in equities involves material risk, including the risk of loss of principal. Please consult a SEBI-registered investment advisor before making any investment decision. The author(s) may or may not hold positions in the securities discussed. Data sourced from NSE, BSE, Screener.in, Trendlyne, and company filings as of March 2026.

Hot this week

HDFC Bank Technical Analysis November 2026

HDFC Bank closed at ₹788.25 on 6 Nov 2026, up about 17.8% from its 52-week low. This technical analysis covers moving averages, RSI, MACD, pivots, Fibonacci levels, volume and scenarios using cross-checked data

What Is Fundamental Analysis of a Stock? Complete Guide with Example

Fundamental analysis estimates what a company's shares are truly worth by studying its business, financial statements and growth outlook. This guide covers the key ratios, valuation methods and a step-by-step worked example

Aster DM Quality Care (ASTERDM) stock Analysis November 2026

Aster DM Quality Care’s merger with Quality Care India created a 39-hospital, ~10,600-bed platform. This analysis weighs five valuation methods, news and sentiment to estimate a fair value of ₹514 against a CMP of ₹719.55

Asian Paints Share Price Target, Fundamental & Technical Analysis November 2026

Asian Paints (NSE: ASIANPAINT) fundamental and technical analysis after Q2 FY27: five valuation methods, a weighted fair value of ₹1,493 against a CMP of ₹2,523.80, buy and sell ranges, risks, and key support and resistance levels

Marico Ltd (NSE: MARICO) Share Price Target 2026: Stock Analysis & Fair Value

Marico's Q2 FY27 brought 10% India volume growth, 27% EBITDA growth and raised FY27 guidance. This Zumedha analysis values the stock with DCF, peer multiples, NAV, EPV and SOTP, and arrives at a Weighted Fair Value of ₹583 against a CMP of ₹878, with buy and sell ranges, scenarios and risks

Topics

Laurus Labs — DCF analysis March 2026

Laurus Labs — Investment Research Report:root { ...

Larsen & Toubro (L&T) Share Price Valuation & Analysis Sept 2026

.zumedha-report{ --ink:#1a1208; --paper:#faf7f2; --cream:#f2ede4; --red:#c8381e; --gold:#b8860b; --green:#1a6b3a; --blue:#1a3f6b;...

Max Healthcare Institute (MAXHEALTH) Share Price & Stock Analysis Sep 2026

.zumedha-report{--ink:#1a1208;--paper:#faf7f2;--cream:#f2ede4;--red:#c8381e;--gold:#b8860b;--green:#1a6b3a;--blue:#1a3f6b;--muted:#6b6255;--accent:#A6192E;--accent-dark:#7C1322;--accent-light:#D98A98;--accent-muted:#B5677A;background:var(--paper);color:var(--ink);font-family:'Source Serif 4',Georgia,serif;line-height:1.65;max-width:1180px;margin:0 auto;font-size:16px;} .zumedha-report *{box-sizing:border-box;} .zumedha-report h1,.zumedha-report h2,.zumedha-report h3,.zumedha-report h4{font-family:'Playfair...

Indian Hotels Valuation Report March 2026

https://zumedha.com/indian-hotels-dcf-valuation-share-price-analysis-aug-2026/Indian Hotels DCF Valuation & Share Price Analysis March...

Ion Exchange (India) Ltd DCF Valuation & Stock Analysis Report

@import url('https://fonts.googleapis.com/css2?family=Playfair+Display:wght@600;800&family=Source+Serif+4:wght@400;600&family=IM+Fell+English+SC&family=JetBrains+Mono:wght@400;700&display=swap'); .zumedha-report{--ink:#1a1208;--paper:#faf7f2;--cream:#f2ede4;--red:#c8381e;--gold:#b8860b;--green:#1a6b3a;--blue:#1a3f6b;--muted:#6b6255;--accent:#0b5aa8;--accent-dark:#083e75;--accent-light:#e3eef9;--accent-muted:#5f86ad;font-family:'Source Serif 4',Georgia,serif;background:var(--paper);color:var(--ink);line-height:1.65;font-size:16px} .zumedha-report *{box-sizing:border-box} .zumedha-report h1,.zumedha-report h2,.zumedha-report h3{font-family:'Playfair Display',serif;margin:0} .zr-masthead{background:var(--accent-dark);color:#fff;padding:18px...

Acutaas Chemicals Limited Stock Price Valuation Analysis as on June 2026

/* ============================================================ ZUMEDHA EQUITY RESEARCH — ACUTAAS...

Vijaya Diagnostic Share Price Analysis April 2026

Vijaya Diagnostic Centre — Zumedha Insights:root { ...

Related Articles